Company: BLTE
Filing Date: 2025-12-02
Form Type: 6-K
Source: 0001104659-25-117690
Chunk: 0

Company: BELITE BIO, INC
Filing Date: 2025-12-02
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-41359

Belite Bio, Inc

(Exact name of registrant as specified in its charter)

Not Applicable

(Translation of Registrant´s name into English)

12750 High Bluff Drive Suite 475,

San Diego, CA 92130

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form
40-F ¨</div>

On December 1, 2025, Belite Bio, Inc (the
“Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co.
LLC, Leerink Partners LLC and BofA Securities, Inc., as representatives of the underwriters named therein, relating to the underwritten
public offering (the “Offering”) of 2,272,727 American Depositary Shares, or
ADSs, each representing one ordinary share, at a public offering price of $154.00 per
ADS. The Company has also granted the underwriters a 30-day option to purchase up to 340,909 additional ADSs from the Company at the public
offering price, less underwriting discounts and commissions. The gross proceeds of the Offering to the Company are expected to be approximately
$350.0 million before deducting underwriting
discounts and commissions and offering expenses payable by the Company. The Offering is expected to close on or about December 3, 2025, subject to the satisfaction
of customary closing conditions.

The Offering was made pursuant to the Company’s
automatic shelf registration statement on Form F-3 (File No. 333-284521), which became effective automatically on January 27, 2025, as
supplemented by a prospectus supplement dated December 1, 2025.

A copy of the Underwriting Agreement is attached
hereto as Exhibit 1.1 and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement do not purport
to be complete and are subject